Furthermore, CA 19-9 demonstrated higher sensitivity and specificity (52% and 80%, respectively) compared to CEA (51% and 72%, respectively) for the prediction of tumor burden in patients with GBC [123]. The gene discussed is CEACAM5; the disease is neoplasm.